Form 8-K

8-K — CITIUS ONCOLOGY, INC.

Accession: 0001213900-26-057883

Filed: 2026-05-15

Period: 2026-05-15

CIK: 0001851484

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — ea0291035-8k_citius.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED MAY 15, 2026 (ea029103501ex99-1.htm)

GRAPHIC (ea029103501_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0291035-8k_citius.htm · Sequence: 1

false

0001851484

2026-05-15

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

May 15, 2026

Citius Oncology, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-41534

99-4362660

(Commission File Number)

(IRS Employer

Identification No.)

11 Commerce Drive, 1st Floor, Cranford, NJ

07016

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code (908) 967-6677

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

CTOR

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On May 15, 2026, Citius Oncology, Inc. (the “Company,”

“we,” or “our”) issued a press release announcing our results of operations for the second quarter of fiscal 2026.

A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information in this

Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of

1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by

reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such

a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press release, dated May 15, 2026.

104

Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CITIUS ONCOLOGY, INC.

Date: May 15, 2026

/s/ Leonard Mazur

Leonard Mazur

Chairman and Chief Executive Officer

EX-99.1 — PRESS RELEASE, DATED MAY 15, 2026

EX-99.1

Filename: ea029103501ex99-1.htm · Sequence: 2

Exhibit

99.1

Citius

Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

$5.6

million in net revenue for the first half of fiscal 2026 as LYMPHIR® launch progresses

to $36.5 million in debt and equity capital secured

Broad

payer coverage established with no reimbursement denials

83%

of target accounts on formulary or in review

CRANFORD,

N.J., May 15, 2026 – Citius Oncology, Inc. (“Citius Oncology” or the “Company”) (Nasdaq: CTOR), the

oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), today reported financial results

for the fiscal second quarter ended March 31, 2026, and provided a business update.

“LYMPHIR’s

commercial launch gives us confidence in the trajectory ahead. In the first six months of fiscal 2026, which includes only four months

of commercial sales since LYMPHIR’s December 2025 launch, we generated $5.6 million in net revenue at gross margins of approximately

80%. This reflects initial orders by distributors during the first quarter, and subsequent reorders during the second quarter as we begin

to see increased institutional demand for the therapy. As leading medical centers continue to add LYMPHIR to formulary and we build out

our sales force, we believe we are moving through the expected transition from initial channel fill to sustained treatment-driven demand.

We have achieved strong institutional penetration for a newly launched specialty therapy, with 83% of our target accounts having added

LYMPHIR or actively progressing it through formulary review. Payer coverage has expanded to near 100% of covered commercial lives, with

no reimbursement denials reported to date,” said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology and Citius

Pharma.

“With

market access efforts underway, our focus is on establishing LYMPHIR’s position in the CTCL treatment journey. The financing we

secured, subsequent to quarter end, is the catalyst that provides us with resources to complete the buildout of our commercial field

force. We expect to have the full commercial team deployed by mid-summer. We have ample finished goods and work-in-process inventory

on hand to support anticipated commercial demand for the foreseeable future. A fully staffed sales organization, reinforced by broad

market access and sufficient inventory to support anticipated demand, is how we plan to drive continued momentum. The fundamentals of

a successful specialty pharmaceutical launch, which include strong formulary and payer access, a funded commercial buildout, and healthy

margins, are all moving in the right direction,” added Mazur.

“Building

on the commercial foundation we are establishing in the U.S., we have initiated our first European shipment as part of the international

distribution agreements we have in place across 19 markets in Southern Europe, the Middle East, and additional Western and Eastern European

territories. At the same time, we continue to strengthen LYMPHIR’s long-term value proposition through our support of clinical

evidence generation. Recent preliminary topline Phase 1 investigator-initiated trial data reinforce the immuno-oncology rationale for

LYMPHIR in combination settings, including its T-regulatory cell (Treg) depletion mechanism, and we look forward to additional data readouts

in the future. Together, these execution milestones and data-driven catalysts reinforce our view that LYMPHIR can be developed beyond

U.S. CTCL as a platform asset in combination regimens. We look forward to sharing continued positive momentum as LYMPHIR establishes

itself as a meaningful new option in the treatment of relapsed or refractory CTCL, and we remain confident in its broader long-term commercial

potential,” concluded Mazur.

Fiscal

Second Quarter 2026 Business Highlights and Subsequent Developments

● Advanced

formularly inclusion with 83% of target accounts having added or actively progressing LYMPHIR

through formulary review;

● Secured

near 100% of covered commercial lives; no reimbursement denials or prior authorization barriers

reported;

● Initiated

community infusion center penetration, with patients beginning to transition from larger

academic cancer centers, a critical next phase of commercial scaling;

● Initiated

shipment of LYMPHIR to Europe, with LYMPHIR being made available through Named Patient Programs

(NPPs) per local regulations;

● Continued

deployment of a proprietary AI-powered machine learning platform to support targeted physician

engagement and efficient penetration of the highly concentrated CTCL prescriber base;

● Recruited

and trained initial field sales team, with expanded field force recruitment underway;

● Announced

positive topline results from two investigator-initiated Phase 1 studies evaluating LYMPHIR

in combination settings, including:

○ Phase

1 trial of LYMPHIR in combination with pembrolizumab (KEYTRUDA®) in patients with recurrent or refractory gynecologic cancers, including

ovarian and endometrial malignancies;

○ Phase

1 trial of LYMPHIR administered prior to CAR-T therapy in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma

(DLBCL), with positive topline safety and efficacy results; and,

● Initiated

evaluation of new bulk drug substance (BDS) suppliers with letter of intent with a new contract

manufacturing organization (CMO) expected by the end of June 2026; $22.7 million of finished

goods and work-in-process inventory as of March 31, 2026 to support anticipated commercial

demand during the transition;

Fiscal

Second Quarter 2026 Financial Highlights and Subsequent Developments

● Cash

and cash equivalents of $2.6 million as of March 31, 2026, prior to the up to $36.5 million

concurrent debt and equity financings that closed in early May 2026;

● Secured

up to $36.5 million in combined financing subsequent to quarter end, consisting of:

○ a

senior secured term loan facility of up to $25 million from Avenue Venture Opportunities Fund II, L.P. (Avenue Capital Group), with $10

million funded at close on May 6, 2026, up to $7 million available beginning October 1, 2026 subject to revenue and liquidity milestones,

and up to $8 million available beginning January 1, 2027 subject to additional revenue milestones; and,

○ approximately

$11.5 million in gross proceeds received May 5, 2026 from the exercise of certain outstanding warrants; and,

● Net

product revenues of $1.7 million for the three months ended March 31, 2026, compared to no

revenue for the three months ended March 31, 2025; and $5.6 million for the six months ended

March 31, 2026, compared to no revenue for the six months ended March 31, 2025;

● Gross

profit of $1.3 million (80% margin) for the three months ended March 31, 2026, and $4.5 million

(80% margin) for the six months ended March 31, 2026;

● R&D

expenses of $1.1 million for the three months ended March 31, 2026, compared to $3.1 million

for the three months ended March 31, 2025; and $2.1 million for the six months ended March

31, 2026, compared to $4.4 million for the six months ended March 31, 2025;

● G&A

expenses of $23.6 million for the three months ended March 31, 2026, compared to $2.2 million

for the three months ended March 31, 2025, primarily driven by the $19.7 million one-time

CMO contract cancellation charge. G&A expenses were $26.5 million for the six months

ended March 31, 2026, compared to $5.6 million for the six months ended March 31, 2025;

● Stock-based

compensation expense of $3.5 million for the three months ended March 31, 2026, compared

to $2.1 million for the three months ended March 31, 2025; and $7.5 million for the six months

ended March 31, 2026, compared to $3.9 million for the six months ended March 31, 2025;

● Recognized

a gain of $1.76 million from the sale of New Jersey state net operating losses under the

New Jersey Technology Business Tax Certificate Transfer Program; and,

● Net

loss of $26.6 million for the three months ended March 31, 2026, compared to a net loss of

$7.7 million for the three months ended March 31, 2025; and a net loss of $32.1 million for

the six months ended March 31, 2026, compared to a net loss of $14.4 million for the six

months ended March 31, 2025.

Fiscal

Second Quarter 2026 Financial Results:

Liquidity

of March 31, 2026, the Company had $2.6 million in cash and cash equivalents.

Subsequent

to quarter end, on May 5, 2026, the Company received approximately $11.5 million in gross proceeds from the exercise of certain outstanding

warrants, and on May 6, 2026, the Company funded $10 million in gross proceeds under the first tranche of a senior secured term loan

facility with Avenue Capital Group providing access to up to $25 million in total gross proceeds.

plan to continue to partially rely on funding from Citius Pharma, to raise capital through equity and debt financings, and to generate

revenue from sales of LYMPHIR. We also have retained Jefferies LLC as our exclusive financial advisor in evaluating strategic alternatives

aimed at maximizing shareholder value.

After

giving effect to the May 2026 equity and debt financings, we expect that Citius Oncology and Citius Pharma collectively will have sufficient

funds to continue operations through November 2026.

Net

Revenue

Net

product revenues were $1.7 million for the three months ended March 31, 2026, compared to no revenue for the three months ended March

31, 2025. For the six months ended March 31, 2026, net product revenues were $5.6 million, compared to no revenue for the six months

ended March 31, 2025.

The

Company launched LYMPHIR in December 2025. The quarterly decrease in product revenues is primarily attributable to larger initial orders

in the quarter ended December 31, 2025, as US distributors established their initial inventories. We believe that revenues will increase

in the future as LYMPHIR gains market acceptance and initial accounts continue placing repeat orders. At the end of April 2026, we announced

an initial shipment of LYMPHIR to Europe.

Research

and Development (R&D) Expenses

R&D

expenses were $1.1 million for the three months ended March 31, 2026, compared to $3.1 million for the three months ended March 31, 2025,

a decrease of $2.0 million. For the six months ended March 31, 2026, R&D expenses were $2.1 million, compared to $4.4 million for

the six months ended March 31, 2025, a decrease of $2.3 million. The decrease in both periods primarily reflects reduced clinical development

activity, as the prior-year periods included costs for a pre-license inspection batch of LYMPHIR previously manufactured.

General

and Administrative (G&A) Expenses

G&A

expenses were $23.6 million for the three months ended March 31, 2026, compared to $2.2 million for the three months ended March 31,

2025, an increase of $21.4 million. For the six months ended March 31, 2026, G&A expenses were $26.5 million, compared to $5.5 million

for the six months ended March 31, 2025, an increase of $21.9 million. The increase in both periods was primarily driven by a $19.7 million

one-time contract cancellation charge related to the CMO termination recognized in March 2026.

Stock-based

Compensation Expense

Stock-based

compensation expense was $3.5 million for the three months ended March 31, 2026, compared to $2.1 million for the three months ended

March 31, 2025. For the six months ended March 31, 2026, stock-based compensation was $7.5 million, compared to $3.9 million for the

six months ended March 31, 2025.

Net

Loss

Net

loss was $26.6 million for the three months ended March 31, 2026, compared to $7.7 million for the three months ended March 31, 2025,

an increase of $18.9 million. For the six months ended March 31, 2026, net loss was $32.1 million, compared to $14.4 million for the

six months ended March 31, 2025, an increase of $17.7 million. The increase in net loss for the three-month period was primarily attributable

to the $19.7 million CMO contract cancellation charge, partially offset by $1.7 million in LYMPHIR revenues and the $1.76 million gain

on the sale of New Jersey net operating losses.

About

Citius Oncology, Inc.

Citius

Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius

Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had

had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing,

and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology,

trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius

Oncology’s competitive positioning. For more information, please visit www.citiusonc.com.

About

Citius Pharmaceuticals, Inc.

Citius

Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class

critical care products. Citius Pharma owns approximately 71% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR,

a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior

systemic therapy. Citius Pharma’s late-stage pipeline also includes Mino-Lok®, a catheter lock solution to salvage

catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of

hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and

secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For

more information, please visit www.citiuspharma.com.

Forward-Looking

Statements

This

press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and

Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future

events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate,"

"estimate," "expect," "plan," "should," and "may" and other words and terms of similar

meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and

uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause

actual results to differ materially from those currently anticipated are: our need for substantial additional funds and our ability to

raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to obtain, perform under

and maintain financing, strategic and third party agreements and relationships, including obtaining a new bulk drug substance supplier;

our ability to regain compliance with Nasdaq’s continued listing standards; our ability to successfully commercialize LYMPHIR and

establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any

market; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to use the latest technology

to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape;

our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability

to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements

and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life

of our target patient populations; risks relating to the results of research and development activities, including those from any new

pipeline assets; our ability to procure cGMP commercial-scale supply; market and other conditions; risks related to our growth strategy;

patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission

(“SEC”) filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these

forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these

forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC’s

website at www.sec.gov, including in Citius Oncology’s Annual Report on Form 10-K for the year ended September 30, 2025, filed

with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation

or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change

in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by

law.

Investor

Contact:

Ilanit

Allen

ir@citiuspharma.com

908-967-6677

x113

Media

Contact:

STiR-communications

Greg

Salsburg

Greg@STiR-communications.com

–

Financial Tables Follow –

CITIUS

ONCOLOGY, INC.

CONDENSED

CONSOLIDATED BALANCE SHEETS

(Unaudited)

March 31,

2026

September 30,

2025

Current Assets:

Cash and cash equivalents

$ 2,632,634

$ 3,924,908

Accounts receivable, net of allowances

1,079,055

—

Inventory

22,659,590

22,286,693

Prepaid expenses

3,052,387

1,331,280

Total Current Assets

29,423,666

27,542,881

Other Assets:

In-process research and development, net of accumulated amortization

71,106,250

73,400,000

Deferred financing costs

169,252

—

Total Other Assets

71,275,502

73,400,000

Total Assets

$ 100,699,168

$ 100,942,881

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:

Accounts payable

$ 8,883,239

$ 13,234,684

License payable

17,650,000

22,650,000

Accrued expenses

24,057,573

4,093,124

Due to related party

8,221,486

9,513,771

Total Current Liabilities

58,812,298

49,491,579

Deferred tax liability

2,817,990

2,784,960

Note payable to related party

3,800,111

Total Liabilities

65,430,399

56,076,650

Stockholders’ Equity:

Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding

—

Common stock - $0.0001 par value; 400,000,000 shares authorized at March 31, 2026 and September 30, 2025; 92,981,204 and 83,513,442 shares issued and outstanding at March 31, 2026 and September 30, 2025, respectively

9,298

8,351

Additional paid-in capital

131,443,191

108,897,836

Accumulated deficit

(96,183,720 )

(64,039,956 )

Total Stockholders’ Equity

35,268,769

44,866,231

Total Liabilities and Stockholders’ Equity

$ 100,699,168

$ 100,942,881

CITIUS

ONCOLOGY, INC.

CONDENSED

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR

THE THREE AND Six Months Ended March 31, 2026 and 2025

(Unaudited)

Three Months Ended

Six Months Ended

March 31,

2026

2025

2026

2025

Revenues

$ 1,667,298

$ —

$ 5,611,409

$ —

Cost of revenues

(328,878 )

—

(1,118,086 )

—

Gross Profit

1,338,420

—

4,493,323

—

Operating Expenses

Research and development

1,079,354

3,139,413

2,097,706

4,403,921

Amortization of in-process research and development

1,720,312

—

2,293,750

—

General and administrative

23,625,639

2,243,327

26,484,978

5,565,306

Stock-based compensation – general and administrative

3,526,710

2,088,572

7,482,760

3,897,050

Total Operating Expenses

29,952,015

7,471,312

38,359,194

13,866,277

Operating Loss

(28,613,595 )

(7,471,312 )

(33,865,871 )

(13,866,277 )

Other Income (Expense)

Interest income

43,721

—

72,009

—

Gain on sale of New Jersey net operating losses

1,762,000

—

1,762,000

—

Interest expense

(33,031 )

—

(78,872 )

—

Total Other Income

1,772,690

—

1,755,137

—

Loss before Income Taxes

(26,840,905 )

(7,471,312 )

(32,110,734 )

(13,866,277 )

Income tax expense (benefit)

(231,210 )

264,240

33,030

528,480

Net Loss

$ (26,609,695 )

$ (7,735,552 )

$ (32,143,764 )

$ (14,394,757 )

Net Loss Per Share - Basic and Diluted

$ (0.27 )

$ (0.11 )

$ (0.34 )

$ (0.20 )

Weighted Average Common Shares Outstanding

Basic and diluted (includes pre-funded warrants from the December 2025 offering)

100,027,204

71,552,402

93,657,757

71,552,402

CITIUS

ONCOLOGY, INC.

Condensed

Consolidated STATEMENTS OF CASH FLOWS

FOR

THE Six Months Ended March 31, 2026 and 2025

(Unaudited)

2026

2025

Cash Flows From Operating Activities:

Net loss

$ (32,143,764 )

$ (14,394,757 )

Adjustments to reconcile net loss to net cash provided by operating activities:

Stock-based compensation expense

7,482,760

3,897,050

Amortization of in-process research and development

2,293,750

Deferred income tax expense

33,030

528,480

Changes in operating assets and liabilities:

Accounts receivable, net of allowances

(1,079,055 )

Inventory

(372,897 )

(7,070,487 )

Prepaid expenses

(1,721,107 )

Accounts payable

(4,351,445 )

3,964,688

Accrued expenses

19,964,449

8,722,168

Due to related party

(1,292,285 )

4,352,858

Net Cash (Used In) Provided By Operating Activities

(11,186,564 )

Cash Flows From Investing Activities

License payments

(5,000,000 )

Net Cash Used In Investing Activities

(5,000,000 )

Cash Flows From Financing Activities

Deferred financing costs

(169,252 )

Net proceeds from issuance of common stock

15,063,542

Net Cash Provided by Financing Activities

14,894,290

Net Change in Cash and Cash Equivalents

(1,292,274 )

Cash and Cash Equivalents – Beginning of Period

3,924,908

112

Cash and Cash Equivalents – End of Period

$ 2,632,634

$ 112

Supplemental Disclosures of Cash Flow Information and Non-cash Transactions:

Interest Paid

$ 14,460

$ -

GRAPHIC

Filename: ea029103501_ex99-1img1.jpg · Sequence: 3

Binary file (5100 bytes)

Download ea029103501_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

May 15, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 15, 2026

Entity File Number

001-41534

Entity Registrant Name

Citius Oncology, Inc.

Entity Central Index Key

0001851484

Entity Tax Identification Number

99-4362660

Entity Incorporation, State or Country Code

Entity Address, Address Line One

11 Commerce Drive

Entity Address, Address Line Two

1st Floor

Entity Address, City or Town

Cranford

Entity Address, State or Province

Entity Address, Postal Zip Code

07016

City Area Code

908

Local Phone Number

967-6677

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock

Trading Symbol

CTOR

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration